Glycosaminoglycans

Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine or N-acetylgalactosamine.
DrugDrug NameDrug Indication
DB00407ArdeparinFor prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.
DB01109HeparinUnfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.
DB01225EnoxaparinFor the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
DB06294SemuloparinInvestigated for use/treatment in thrombosis.
DB06754DanaparoidIndicated for the prophylaxis of post-operative deep venous thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients undergoing elective hip replacement surgery [FDA Label].
DB06779DalteparinDalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications. Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes). It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
DB06822TinzaparinTinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.
DB08813NadroparinNadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.
DB08818Hyaluronic acidUsed to treat knee pain in patients with joint inflammation (osteoarthritis). It is usually used in patients who have not responded to other treatments such as acetaminophen, exercise, or physical therapy. Hyaluronic acid may also be used in plastic surgery to reduce wrinkles on the face or as a filler in other parts of the body. May be used in ophthalmology to assist in the extraction of cataracts, the implantation of intraocular lenses, corneal transplants, glaucoma filtration, retinal attachment and in the treatment of dry eyes. Finally, hyaluronic acid is also used to coat the bladder lining in treating interstitial cystitis.
DB09258BemiparinBemiparin is indicated in the following cases: To prevent blood clots in the veins after general abdominal surgery in patients with a moderate risk of venous thromboembolism; in the prevention of the thromboembolic disease in non-surgical patients; prevention of clotting in the extracorporeal circuit during hemodialysis; to prevent blood clots in the veins after a major orthopedic surgery in patients with high risk of venous thromboembolism; secondary prevention of venous thromboembolism; recurrence in patients with deep vein thrombosis; transient prevention and treatment of deep vein thrombosis (DVT) [L1463].
DB09259ReviparinBy the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients.[L1469]
DB09260ParnaparinUsed in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
DB09261CertoparinUsed in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
DB09301Chondroitin sulfateChondroitin sulfate, used with glucosamine, is indicated to alleviate pain and inflammation from primary osteoarthritis.[L1527] This supplement is reported to improve joint function and slow disease progression.[L1528] Osteoarthritis is characterized by progressive structural and metabolic changes in joint tissues, mainly cartilage degradation, subchondral bone sclerosis and inflammation of synovial membrane.[A32066] Studies have proposed the potential use of chondroitin sulfate as a nutraceutical in dietary supplements.[A32065]
DB11598Antithrombin III humanAntithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism
DB00686Pentosan PolysulfateFor the relief of bladder pain or discomfort associated with interstitial cystitis.
DrugDrug NameTargetType
DB00407ArdeparinHeparin cofactor 2target
DB00407ArdeparinAntithrombin-IIItarget
DB01109HeparinAntithrombin-IIItarget
DB01109HeparinCoagulation factor Xtarget
DB01109HeparinP-selectintarget
DB01109HeparinHeparanaseenzyme
DB01109HeparinFibroblast growth factor receptor 4target
DB01109HeparinFibroblast growth factor 4target
DB01109HeparinFibroblast growth factor 19target
DB01109HeparinFibroblast growth factor receptor 1target
DB01109HeparinFibroblast growth factor 1target
DB01109HeparinFibroblast growth factor receptor 2target
DB01109HeparinFibroblast growth factor 2target
DB01109HeparinPlatelet factor 4target
DB01109HeparinHepatocyte growth factortarget
DB01109HeparinThyroxine-binding globulincarrier
DB01225EnoxaparinAntithrombin-IIItarget
DB01225EnoxaparinCoagulation factor Xtarget
DB01225EnoxaparinMyeloperoxidaseenzyme
DB06754DanaparoidAntithrombin-IIItarget
DB06779DalteparinVascular endothelial growth factor Atarget
DB06779DalteparinTissue factor pathway inhibitortarget
DB06779DalteparinHeparanaseenzyme
DB06779DalteparinAntithrombin-IIItarget
DB06779DalteparinP-selectintarget
DB06822TinzaparinAntithrombin-IIItarget
DB06822TinzaparinA disintegrin and metalloproteinase with thrombospondin motifs 4enzyme
DB06822TinzaparinIntegrin alpha-4target
DB06822TinzaparinStromal cell-derived factor 1target
DB08813NadroparinProto-oncogene c-Fostarget
DB08813NadroparinMyc proto-oncogene proteintarget
DB08813NadroparinP-selectintarget
DB08813NadroparinAntithrombin-IIItarget
DB08818Hyaluronic acidCD44 antigentarget
DB08818Hyaluronic acidIntercellular adhesion molecule 1target
DB08818Hyaluronic acidHyaluronan mediated motility receptortarget
DB08818Hyaluronic acidNeurocan core proteintarget
DB08818Hyaluronic acidVersican core proteintarget
DB08818Hyaluronic acidComplement component 1 Q subcomponent-binding protein, mitochondrialtarget
DB08818Hyaluronic acidHyaluronan and proteoglycan link protein 1target
DB08818Hyaluronic acidHyaluronan and proteoglycan link protein 3target
DB08818Hyaluronic acidHyaluronan and proteoglycan link protein 4target
DB08818Hyaluronic acidHyaluronan-binding protein 2target
DB08818Hyaluronic acidLayilintarget
DB08818Hyaluronic acidStabilin-2target
DB08818Hyaluronic acidTumor necrosis factor-inducible gene 6 proteintarget
DB08818Hyaluronic acidInterphotoreceptor matrix proteoglycan 2target
DB08818Hyaluronic acidIntracellular hyaluronan-binding protein 4target
DB09258BemiparinCoagulation factor Xtarget
DB09258BemiparinPlasma serine protease inhibitorenzyme
DB09258BemiparinAntithrombin-IIItarget
DB09258BemiparinHeparin cofactor 2target
DB09301Chondroitin sulfateBrain-derived neurotrophic factortarget
DB09301Chondroitin sulfateGlial cell line-derived neurotrophic factortarget
DB09301Chondroitin sulfateVascular endothelial growth factor Atarget
DB09301Chondroitin sulfateC-C motif chemokine 2target
DB09301Chondroitin sulfateBeta-glucuronidaseenzyme
DB09301Chondroitin sulfateBeta-hexosaminidase subunit betaenzyme
DB09301Chondroitin sulfateN-acetylgalactosamine-6-sulfataseenzyme
DB09301Chondroitin sulfateIduronate 2-sulfataseenzyme
DB09301Chondroitin sulfateAlpha-L-iduronidaseenzyme
DB09301Chondroitin sulfateArylsulfatase Benzyme
DB09301Chondroitin sulfateGlucuronate-2-sulfataseenzyme
DB11598Antithrombin III humanAntithrombin-IIItarget
DB00686Pentosan PolysulfateFibroblast growth factor 1target
DB00686Pentosan PolysulfateFibroblast growth factor 4target
DB00686Pentosan PolysulfateFibroblast growth factor 2target